Cairn Biosciences' CEO details company's pursuit of new tools to enable cancer drug discovery

At the Xcelerate Startup Pitch Competition hosted by EBD Group and Xcelerate Insight during Biotech Week Boston in September, 2018, CEO Mary Ludlam of Cairn Biosciences was second runner up for Best Business Plan. Cairn is developing next-generation therapeutics that address significant challenges in the treatment of cancer, discovering new tools to decipher cellular complexity and enable development of groundbreaking therapies. The pitch competition is designed to give early stage companies exposure to possible investors and partners, and is judged by top venture capitalists and industry experts.